ELEMENT
23.8.2022 06:02:17 CEST | Business Wire | Press release
Today at ACHEMA, Element , a leading provider of operations data management software to global industrials, announced a partnership with IPCOS , a global industrial digitalization solution provider, to bring increased efficiency and predictability to chemical plant customers through the Unify platform. Unify makes siloed, fragmented operations data useful for people to deliver expert analysis and guidance from anywhere, at any time.
“Through our close partnership with Element, IPCOS’ customers will gain access to the popular Unify platform closing the gap between MES and Cloud. With Unify, we can implement effective data management strategies integrating traditional data models developed at the MES layer with modern Cloud solutions. IPCOS believes this will be a significant accelerator for digitalization in the process industry, leading to increased effectiveness of their chemical processing operations,” said Filip Stroobant, Managing Director Digital Assets, IPCOS.
“We’re excited to partner with IPCOS to enable chemical operators who are racing to turn their exponentially growing operations data into a value-generating asset so their people can make faster decisions. Together, IPCOS and Element empower people with operations data to achieve analytical insights that improve on-stream time, resiliency, sustainability and profit,” said Andy Bane, CEO of Element.
Together, IPCOS and Element accelerate digital solutions that maximize the efficiency and sustainability of industrial plant operations. IPCOS’ deep knowledge of data-centric initiatives and ability to deliver greater value from industrial operations to their customers is further enhanced with the Unify operations data management platform, helping customers to reach their digital transformation initiatives faster, cheaper and at greater scale.
Element will be exhibiting at the ACHEMA Conference in Frankfurt, Germany August 22-26, 2022. Stop by the Element booth (Hall 11.0, Stand F54) to learn more about the company’s partnership with IPCOS and to receive a demonstration of the Unify platform, and/or read more in the Element blog post here .
About Element
Element is a leading software provider in operations data management. Element Unify empowers people with access to operations data to make faster decisions that deliver financial impact. Element’s customers represent over $750 billion in revenue, $500 billion in fixed assets and 450,000 employees. To learn more about Element, please visit elementanalytics.com
and follow the company on LinkedIn
and Twitter
.
About IPCOS
IPCOS is a services provider that maximizes the performance of its customers’ assets in the international chemical and energy industries. IPCOS experts implement tailor-made, state-of-the-art technology to increase plant operations efficiency and integrate information technologies into customer workflows to improve industrial processes. With an extensive track record, IPCOS is trusted to deliver unique engineering-based, technology-independent solutions that combine domain knowledge with technology know-how. For more information visit IPCOS.com
and follow the company on LinkedIn
and Twitter
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220822005705/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom